Ecthyma gangrenosum and ecthyma-like lesions: review article
- 1.6k Downloads
The generally accepted definition of ecthyma gangrenosum (EG) states that this condition is pathognomonic of Pseudomonas septicemia (Pseudomonas aeruginosa) and that it should usually be seen in immunocompromised patients, particularly those with underlying malignant disease. The cases described in the literature present a somewhat different picture. Our objective was to analyze this controversy. The review analyzes 167 cases of EG that were described in the literature from 1975 to 2014. All articles on EG cases with EG-specific tissue defect that had signs of general and/or local infection and skin necrosis were included and analyzed, whatever the etiology detected. Necrotic lesions of the skin diagnosed as EG have various microbiological etiology, can occur in immunocompetent or even healthy persons, and are not necessarily connected with septicemia. In published cases, P. aeruginosa was detected in 123 cases (73.65 %); of them, there were only 72 cases (58.5 %) with sepsis. Other bacterial etiology was detected in 29 cases (17.35 %) and fungi were detected in 15 cases (9 %). While the clinical picture of the disease and the treatment strategy remain the same, there is no need to invent two separate definitions for Pseudomonas and non-Pseudomonas cases. We suggest accepting a broader definition of EG.
KeywordsFamilial Mediterranean Fever Skin Necrosis Pyoderma Gangrenosum Immunocompromised Status Metarhizium Anisopliae
Conflict of interest
Disclosure of potential conflicts of interest: the authors state no potential conflict of interest.
Compliance with ethical standards
Research involving human participants and/or animals: N/A.
Informed consent: N/A.
- 37.Pathak A, Singh P, Yadav Y, Dhaneria M (2013) Ecthyma gangrenosum in a neonate: not always pseudomonas. BMJ Case Rep. doi: 10.1136/bcr-2013-009287
- 38.Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN; Antimicrobial Susceptibility Testing Subcommittee of the Clinical and Laboratory Standards Institute (2013) Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam. Clin Infect Dis 56(9):1301–1309. doi: 10.1093/cid/cit017 CrossRefPubMedGoogle Scholar
- 39.Ho PL, Chow KH, Tse H, Cheng VC (2012) Effect of applying the new Clinical and Laboratory Standards Institute ticarcillin/clavulanic acid, piperacillin, piperacillin/tazobactam and imipenem susceptibility breakpoints for Pseudomonas aeruginosa in Hong Kong. Int J Antimicrob Agents 40(3):280–281. doi: 10.1016/j.ijantimicag.2012.05.008 CrossRefPubMedGoogle Scholar
- 40.Nakamura T, Shimizu C, Kasahara M, Nakata C, Munakata M, Takahashi H (2007) Differences in antimicrobial susceptibility breakpoints for Pseudomonas aeruginosa, isolated from blood cultures, set by the Clinical and Laboratory Standards Institute (CLSI) and the Japanese Society of Chemotherapy. J Infect Chemother 13(1):24–29CrossRefPubMedGoogle Scholar